Phase 2 RCT | Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease.

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Clinical trial finds novel therapy markedly reduced lipoprotein(a) levels in people with cardiovascular disease – Brigham and Women’s Hospital

Commentary on Twitter

Lipoprotein(a) is similar to LDL cholesterol but contains apolipoprotein(a). A trial tested the effects of an oligonucleotide drug targeting apo(a) mRNA on lipoprotein(a) concentrations in patients with CVD. #AHA22 https://t.co/eLgnrnTm5D pic.twitter.com/QmNUcxeJwX

— NEJM (@NEJM) November 6, 2022